UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037739
Receipt number R000042791
Scientific Title Identification of gene polymorphisms that predict the efficacy and safety of nivolumab treatment for renal cancer
Date of disclosure of the study information 2019/08/20
Last modified on 2020/08/19 15:07:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Identification of gene polymorphisms that predict the efficacy and safety of nivolumab treatment for renal cancer

Acronym

SNiP-RCC

Scientific Title

Identification of gene polymorphisms that predict the efficacy and safety of nivolumab treatment for renal cancer

Scientific Title:Acronym

SNiP-RCC

Region

Japan


Condition

Condition

Renal cell cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To identify genetic polymorphisms that predict the efficacy and safety of nivolumab treatment for renal cancer by genome-wide analysis on single-nucleotide polymorphism (SNP).

Basic objectives2

Others

Basic objectives -Others

To carry out genome-wide SNP analysis of genome DNA extracted from blood specimen using Japonica array.

Trial characteristics_1

Others

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

SNPs that correlate with tumor response to nivolumab

Key secondary outcomes

SNPs that correlate with progression , treatment continuation and overall survival in nivolumab treatment SNPs that correlate with adverse events in nivolumab treatment


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Patients who were treated or are planned to be treated with nivolumab for advanced renal cancer
2.Patients diagnosed with clear cell carcinoma pathologically
3.Patients with at least one measurable lesion according to RECIST v1.1 criteria
4.Patients who fully understand this research plan and can give their consent
5.Japanese people over 20 years of age at the time of consent acquisition

Key exclusion criteria

1.non-Japanese patients
2.Patients in whom the evaluation of response rate according to RECIST ver.1.1 is not carried out within 24 weeks after the start of treatment
3.Patients who received nivolumab as first line treatment
4.Patients who co-administered with drugs for renal cancer other than nivolumab
5.Patients who are judged inappropriate for participation in this study

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Masatoshi
Middle name
Last name Eto

Organization

Graduate School of Medical Sciences, Kyushu University

Division name

Department of Urology

Zip code

812-8582

Address

3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan

TEL

092-642-5601

Email

etom@uro.med.kyushu-u.ac.jp


Public contact

Name of contact person

1st name Masaki
Middle name
Last name Shiota

Organization

Kyushu University Hospital

Division name

Department of Urology

Zip code

812-8582

Address

3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan

TEL

092-642-5603

Homepage URL


Email

shiota@uro.med.kyushu-u.ac.jp


Sponsor or person

Institute

Graduate School of Medical Sciences, Kyushu University

Institute

Department

Personal name



Funding Source

Organization

ONO PHARMACEUTICAL CO., LTD.
Bristol-Myers Squibb K.K.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

(Not for public release)Entered

Address

(Not for public release)Entered

Tel

(Not for public release)Entered

Email

(Not for public release)Entered


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道大学大学院医学研究科(北海道)、札幌医科大学医学部(北海道)、弘前大学大学院医学研究科(青森県)、岩手医科大学医学部(岩手県)、山形大学医学部(山形県)、新潟大学大学院医歯学総合研究科(新潟県)、慶應義塾大学医学部(東京都)、防衛医科大学校(埼玉県)、浜松医科大学医学部(静岡県)、名古屋大学大学院医学系研究科(愛知県)、京都大学大学院医学研究科(京都府)、大阪大学大学院医学系研究科(大阪府)、近畿大学医学部(大阪府)、奈良県立医科大学(奈良県)、神戸大学大学院医学研究科(兵庫県)、広島市立安佐市民病院(広島県)、山口大学大学院医学系研究科(山口県)、徳島大学大学院医歯薬学研究部(徳島県)、国立病院機構四国がんセンター(愛媛県)、九州大学大学院医学研究院(福岡県)、熊本大学大学院生命科学研究部(熊本県)、長崎大学大学院医歯薬学総合研究科(長崎県)、宮崎大学医学部(宮崎県)、鹿児島大学大学院医歯学総合研究科(鹿児島県)


Other administrative information

Date of disclosure of the study information

2019 Year 08 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 04 Month 24 Day

Date of IRB

2019 Year 08 Month 19 Day

Anticipated trial start date

2019 Year 09 Month 06 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

1.Extraction of DNA from blood specimen.
2. SNP analysis using Japonica array.
3.Individual SNP analysis using PCR method.
4.Statistical analysis of correlation with clinical information.


Management information

Registered date

2019 Year 08 Month 20 Day

Last modified on

2020 Year 08 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042791


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name